Cetuximab + Gemox in Biliary Tract Cancer
The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary tract cancer (BTC) patients.
Unresectable|Locally Advanced|Metastatic
DRUG: Cetuximab + Gemcitabine + Oxaliplatin
best overall response (according to RECIST 1.0), overall response rate (ORR) will be measured after each 4 cycles (average 2 months) of Cetuximab +GEMOX and the overall best response recorded, after an average of 2 months
Safety of the treatment combination, approximately 6 months
Primary Objective(s) The primary objective of the study is to evaluate the best overall response of cetuximab in combination with gemcitabine and oxaliplatin (GEMOX) as first line treatment in patients with advanced or metastatic biliary tract cancer.

Secondary Objectives

The secondary objectives of this study are as follows:

* toxicity
* secondary resection rate
* progression-free survival (PFS)
* overall survival (OS)